Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-21
2005-06-21
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000
Reexamination Certificate
active
06908930
ABSTRACT:
This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.
REFERENCES:
patent: 5719135 (1998-02-01), Buzzetti et al.
patent: 5811432 (1998-09-01), Marfat et al.
patent: 5916891 (1999-06-01), Adams et al.
patent: 5955592 (1999-09-01), Ullrich et al.
patent: WO 87/04928 (1987-08-01), None
patent: WO 91/09598 (1991-07-01), None
patent: WO 93/20078 (1993-10-01), None
patent: WO 96/16964 (1996-06-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/23613 (1998-06-01), None
patent: WO 99/21859 (1999-05-01), None
patent: WO 99/37622 (1999-07-01), None
Wolff, Manfred E. “Burger'Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Alexander J. Bridges, Chem. Rev., 101 (8), 2541-2571, 2001.
Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE, J Clin Oncol. 2003 May 15;21(10):1980-7.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, p. 596.
Akbasak et al., “Oncogenes: cause or consequence in the development of glial tumors,”Journal of the Neurological Sciences, 1992, pp. 119-133, vol. 111, Elsevier Science Publishers B.V.
Arteaga et al., “Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,”Journal of Clinical Investigation, Nov. 1989, pp. 1418-1423, vol. 84, The American Society for Clinical Investigation, Inc.
Baserga, “Oncogenes and the Strategy of Growth Factors,”Cell Minireview, Dec. 19, 1994, pp. 927-930, vol. 79, Cell Press.
Baserga, “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”Cancer Research, Jan. 15, 1995, pp. 249-252, vol. 55.
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”The FASEB Journal, Dec. 1992, pp. 3403-3409, vol. 6, Bristol-Myers Squibb.
Brott et al., “MEK2 is a Kinase Related to MEK1 and is Differentially Expressed in Murine Tissues,”Cell Growth&Differentiation, Nov. 1993, pp. 921-929, vol. 4, American Association of Cancer Research.
Campbell et al., “Evidence for Involvement of the Growth Hormone Receptor-associated Tyrosine Kinase in Actions of Growth Hormone.”The Journal of Biological Chemistry, 1993, pp. 7427-7434, vol. 268, No. 10, The American Society for Biochemistry and Molecular Biology, Inc.
Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,”International Journal of Cancer, 1993, pp. 571-577, vol. 54, Wiley-Lisa, Inc.
Cleaveland et al., “A Microtiter-Based Assay for the Detection of Protein Tyrosine Kinase Activity,”Analytical Biochemistry, 1990, pp. 249-253, vol. 190, Academic Press, Inc.
Coppola, D. et al., “A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,”Molecular and Cellular Biology, Jul. 1994, pp. 4588-4595, vol. 14, No. 7, American Society for Microbiology.
Damasio, “Alzheimer's disease and related dementias,”Cecil Textbook of Medicine, 20thEdition, 1996, pp. 1992-1996, vol. 2.
Davis et al., Chapter 47, “Animal Cells: Cultivation, Growth Regulation, Transformation,”Microbiology 4thEd., 1990, pp. 838-841, © J. B. Lippincott Company.
Dickson et al., “Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,”Cancer Treatment Research, 1992, pp. 249-273, vol. 61, 1991 Kluwer Academic Publishers, Boston.
Donato et al., “Tumor Necrosis Factor Regulates Tyrosine Phosphorylation in Epidermal Growth Factor Receptors in A431 Carcinoma Cells: Evidence for a Distinct Mechanism,”Cell Growth and Differentiation, May 1992, pp. 259-268, vol. 3.
Farley et al., “Development of Solid-Phase Enzyme-Linked Immunosorbent Assays for the Determination of Epidermal Growth Factor Receptor and pp60c-srcTyrosine Protein Kinase Activity,”Analytical Biochemistry, 1992, pp. 151-157, vol. 203, Academic Press, Inc.
Floege et al., “Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,”Kidney International, 1993, pp. S-47-S-54, vol. 43, Suppl. 39, International Society of Nephrology.
Goldring et al., “Cytokines and Cell Growth Control,”Critical Reviews in Eukaryotic Gene Expression, 1991, pp. 301-326, vol. 1, No. 4.
Hansen et al., “Application of two-dimensional gel analysis to identification and characterization of tyrosine phosphorylated substrates for growth factor receptors,”Electrophoresis, 1993, pp. 112-126, vol. 14, VCH Verlagsgesellschaft mbH, D-6940 Weinheim, 1993.
Katagiri et al., “Tyrosine-Phosphorylation of Tubulin during Monocytic Differentiation of HL-60 Cells,”The Journal of Immunology, Jan. 15, 1993, pp. 585-593, vol. 150, No. 2, The American Association of Immunologists.
Korc et al., “Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,”Journal of Clinical Investigation, Oct. 1992, pp. 1352-1360, vol. 90, The American Society for Clinical Investigation, Inc.
Layzer, “Degenerative diseases of the nervous system,”Cecil Textbook of Medicine, 20thEdition, 1996, pp. 2050-2057, vol. 2.
Lazaro et al., “Description of an Enzyme-Linked Immunosorbent Assay for the Detection of Protein Tyrosine Kinase,”Biochemistry, 1991, pp. 257-261, vol. 192, Academic Press, Inc.
Lee et al., “Intracellular Retention of Membrane-anchored v-sis Protein Abrogates Autocrine Signal Transdution,”The Journal of Cell Biology, Sep. 1992, pp. 1057-1070, vol. 118, The Rockefeller University Press.
Macauley et al., “Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells,”Cancer Research, Apr. 15, 1990, pp. 2511-2517, vol. 50.
Peraldi et al., “Dephosphorylation of human insulin-like growth factor I (IGF-I) receptors by membrane-associated tyrosine phosphatases,”Biochem. J., 1992, pp. 71-78, vol. 285.
Plowman et al., “Receptor Tyrosine Kinases as Targets for Drug Intervention,”DN&P, Aug. 1994, pp. 334-339, vol. 7, No. 6.
Sandbert-Nordqvist et al., “Characterization of insulin-like Growth Factor 1 in Human Primary Brain Tumors,”Cancer Research, Jun. 1, 1993, pp. 2475-2478, vol. 53.
Schraag et al., “Standardization of an Enzyme-Linked Immunosorbent Assay for the Determination of Protein Tyrosine Kinase Activity,”Analytical Biochemistry, 1993, pp. 233-239, vol. 211, Academic Press, Inc.
Simone, “Oncology: Introduction,”Cecil Textbook of Medicine, 20thEdition, 1996, pp. 1004-1010, vol. 1.
Slamon et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer,”Science Reports, May 12, 1989, pp. 707-712, vol. 244, American Association for the Advancement of Science.
Torp et al., “Expression of the epidermal growth factor receptor gene in human brain metastases,”APMIS, 1992, pp. 713-719, vol. 100, The Institute of Cancer Research.
Traxler et al., “Review: Oncologic Endocrine & Metabolic Protein Tyrosine Kinase Inhibitors in Cancer Treatment,”Exp. Opin. Ther. Pat
Cui Jingrong
Hirth Klaus Peter
Liang Congxin
McMahon Gerald
Sun Li
Liptak Vincent P.
McKenzie Thomas C.
Richardson Peter C.
Sugen Inc.
Zielinski Bryan C.
LandOfFree
4-substituted 7-AZA-indolin-2-ones and their use as protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-substituted 7-AZA-indolin-2-ones and their use as protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-substituted 7-AZA-indolin-2-ones and their use as protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486351